<DOC>
	<DOCNO>NCT00235508</DOCNO>
	<brief_summary>To determine safety efficacy eszopiclone adjunctive therapy treatment insomnia patient insomnia relate Generalized Anxiety Disorder . All subject receive approve anxiolytic agent randomize nightly therapy either eszopiclone placebo .</brief_summary>
	<brief_title>Safety Efficacy Eszopiclone Patients With Generalized Anxiety Disorder</brief_title>
	<detailed_description>An 8-week , randomize , double-blind , placebo-controlled , parallel-group adjunctive therapy trial . The study consist subject insomnia relate Generalized Anxiety Disorder treat 10 week open-label escitalopram oxalate 10 mg/day bedtime , randomize receive either eszopiclone 3 mg nightly placebo nightly 8 week . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Subjects , age 18 64 year inclusive Subjects Generalized Anxiety Disorder ( GAD ) Subjects insomnia related GAD .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Insomnia</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Generalized Anxiety Disorder</keyword>
</DOC>